AR040629A1 - Derivados de hidrazono-malonitrilo, los medicamentos que los contienen, uso para la preparacion de un medicamento, un conjunto de elementos (kit) que los comprende, un procedimiento para la preparacion, los intermediarios utiles en dicho procedimiento, y las combinaciones de uno de dichos derivados - Google Patents
Derivados de hidrazono-malonitrilo, los medicamentos que los contienen, uso para la preparacion de un medicamento, un conjunto de elementos (kit) que los comprende, un procedimiento para la preparacion, los intermediarios utiles en dicho procedimiento, y las combinaciones de uno de dichos derivadosInfo
- Publication number
- AR040629A1 AR040629A1 AR20020104169A ARP020104169A AR040629A1 AR 040629 A1 AR040629 A1 AR 040629A1 AR 20020104169 A AR20020104169 A AR 20020104169A AR P020104169 A ARP020104169 A AR P020104169A AR 040629 A1 AR040629 A1 AR 040629A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- formula
- procedure
- preparation
- compounds
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title 3
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 229940079593 drug Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 1
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01125455 | 2001-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040629A1 true AR040629A1 (es) | 2005-04-13 |
Family
ID=8179075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20020104169A AR040629A1 (es) | 2001-11-05 | 2002-11-01 | Derivados de hidrazono-malonitrilo, los medicamentos que los contienen, uso para la preparacion de un medicamento, un conjunto de elementos (kit) que los comprende, un procedimiento para la preparacion, los intermediarios utiles en dicho procedimiento, y las combinaciones de uno de dichos derivados |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7141572B2 (enExample) |
| EP (1) | EP1441730B1 (enExample) |
| JP (1) | JP5116940B2 (enExample) |
| KR (1) | KR100898894B1 (enExample) |
| CN (1) | CN1585641A (enExample) |
| AR (1) | AR040629A1 (enExample) |
| AT (1) | ATE335486T1 (enExample) |
| AU (1) | AU2002363368B2 (enExample) |
| BR (1) | BR0213683A (enExample) |
| CA (1) | CA2465746C (enExample) |
| DE (1) | DE60213841T2 (enExample) |
| ES (1) | ES2268157T3 (enExample) |
| HU (1) | HUP0401747A3 (enExample) |
| MX (1) | MXPA04004263A (enExample) |
| MY (1) | MY129491A (enExample) |
| PL (1) | PL369738A1 (enExample) |
| RU (1) | RU2302412C2 (enExample) |
| WO (1) | WO2003039548A1 (enExample) |
| ZA (1) | ZA200404387B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA82323C2 (uk) * | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань |
| WO2004060346A2 (en) | 2002-12-30 | 2004-07-22 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| US20060083714A1 (en) * | 2003-01-27 | 2006-04-20 | Warner James M | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
| CA2521056A1 (en) * | 2003-03-31 | 2004-10-14 | Daiichi Pharmaceutical Co., Ltd. | Hydrazone derivative |
| PE20060272A1 (es) * | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| AU2006237300B2 (en) * | 2005-04-19 | 2011-10-13 | Takeda Gmbh | Roflumilast for the treatment of pulmonary hypertension |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| ATE478067T1 (de) | 2006-03-31 | 2010-09-15 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| BR122020021551B1 (pt) | 2008-11-15 | 2021-09-21 | Melinta Subsidiary Corp | Composição farmacêutica antimicrobiana e seu uso |
| CN102639700A (zh) | 2009-09-30 | 2012-08-15 | 哈佛大学校长及研究员协会 | 通过调节自噬增强基因产物调节自噬的方法 |
| WO2011163231A2 (en) * | 2010-06-21 | 2011-12-29 | Theracos, Inc. | Combination therapy for the treatment of diabetes |
| US9452173B2 (en) | 2013-01-31 | 2016-09-27 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9446131B2 (en) | 2013-01-31 | 2016-09-20 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9433680B2 (en) | 2013-01-31 | 2016-09-06 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US8778365B1 (en) | 2013-01-31 | 2014-07-15 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| MD20150071A2 (ro) | 2013-02-19 | 2016-02-29 | Pfizer Inc. | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni |
| JO3516B1 (ar) * | 2013-03-06 | 2020-07-05 | Janssen Pharmaceutica Nv | مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4 |
| WO2015054359A1 (en) * | 2013-10-08 | 2015-04-16 | Ebadi Mark A | Methods and compositions for symptomatic reflief of the common cold |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| EA031201B1 (ru) | 2014-08-06 | 2018-11-30 | Пфайзер Инк. | Соединения имидазопиридазина |
| EP3268085A4 (en) | 2015-03-13 | 2018-10-31 | The Board of Trustees of The Leland Stanford Junior University | Ltb4 inhibition to prevent and treat human lymphedema |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8400863D0 (en) * | 1984-01-13 | 1984-02-15 | Smith Kline French Lab | Chemical compounds |
| DE19632549A1 (de) | 1996-08-13 | 1998-02-19 | Merck Patent Gmbh | Arylalkanoylpyridazine |
| DE19826841A1 (de) * | 1998-06-16 | 1999-12-23 | Merck Patent Gmbh | Arylalkanoylpyridazine |
| DE19850701A1 (de) * | 1998-11-04 | 2000-05-11 | Merck Patent Gmbh | Benzoylpyridazine |
| DE19932315A1 (de) * | 1999-07-10 | 2001-01-11 | Merck Patent Gmbh | Benzoylpyridazine |
-
2002
- 2002-10-10 PL PL02369738A patent/PL369738A1/xx not_active Application Discontinuation
- 2002-10-10 ES ES02802625T patent/ES2268157T3/es not_active Expired - Lifetime
- 2002-10-10 AT AT02802625T patent/ATE335486T1/de not_active IP Right Cessation
- 2002-10-10 RU RU2004117171/04A patent/RU2302412C2/ru not_active IP Right Cessation
- 2002-10-10 EP EP02802625A patent/EP1441730B1/en not_active Expired - Lifetime
- 2002-10-10 CN CNA028222164A patent/CN1585641A/zh active Pending
- 2002-10-10 DE DE60213841T patent/DE60213841T2/de not_active Expired - Lifetime
- 2002-10-10 HU HU0401747A patent/HUP0401747A3/hu unknown
- 2002-10-10 JP JP2003541839A patent/JP5116940B2/ja not_active Expired - Fee Related
- 2002-10-10 KR KR1020047006820A patent/KR100898894B1/ko not_active Expired - Fee Related
- 2002-10-10 BR BR0213683-0A patent/BR0213683A/pt not_active IP Right Cessation
- 2002-10-10 CA CA2465746A patent/CA2465746C/en not_active Expired - Fee Related
- 2002-10-10 MX MXPA04004263A patent/MXPA04004263A/es active IP Right Grant
- 2002-10-10 WO PCT/EP2002/011351 patent/WO2003039548A1/en not_active Ceased
- 2002-10-10 US US10/494,631 patent/US7141572B2/en not_active Expired - Fee Related
- 2002-10-10 AU AU2002363368A patent/AU2002363368B2/en not_active Ceased
- 2002-11-01 MY MYPI20024107A patent/MY129491A/en unknown
- 2002-11-01 AR AR20020104169A patent/AR040629A1/es unknown
-
2004
- 2004-06-03 ZA ZA200404387A patent/ZA200404387B/en unknown
-
2006
- 2006-08-02 US US11/497,235 patent/US7544684B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2465746C (en) | 2011-09-06 |
| HUP0401747A2 (hu) | 2005-01-28 |
| DE60213841D1 (de) | 2006-09-21 |
| ES2268157T3 (es) | 2007-03-16 |
| MXPA04004263A (es) | 2004-07-08 |
| AU2002363368B2 (en) | 2007-12-13 |
| KR100898894B1 (ko) | 2009-05-21 |
| EP1441730B1 (en) | 2006-08-09 |
| CN1585641A (zh) | 2005-02-23 |
| WO2003039548A1 (en) | 2003-05-15 |
| US20040261190A1 (en) | 2004-12-30 |
| JP5116940B2 (ja) | 2013-01-09 |
| AU2002363368B9 (en) | 2003-05-19 |
| US7544684B2 (en) | 2009-06-09 |
| RU2302412C2 (ru) | 2007-07-10 |
| JP2005511595A (ja) | 2005-04-28 |
| RU2004117171A (ru) | 2006-01-10 |
| PL369738A1 (en) | 2005-05-02 |
| KR20050035177A (ko) | 2005-04-15 |
| CA2465746A1 (en) | 2003-05-15 |
| US20060270676A1 (en) | 2006-11-30 |
| ATE335486T1 (de) | 2006-09-15 |
| EP1441730A1 (en) | 2004-08-04 |
| ZA200404387B (en) | 2006-02-22 |
| US7141572B2 (en) | 2006-11-28 |
| HUP0401747A3 (en) | 2005-06-28 |
| BR0213683A (pt) | 2004-10-26 |
| MY129491A (en) | 2007-04-30 |
| DE60213841T2 (de) | 2007-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037972A1 (es) | Pirrolopirimidinas | |
| RU2004109812A (ru) | Ингибиторы цистеинпротеазы 2-циано-4-аминопиримидинового строения с ингибирующим действием на катепсин к для лечения воспалительных и других заболеваний | |
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| UY28374A1 (es) | Agentes terapéuticos | |
| AR057712A1 (es) | Dihidropteridinonas en el tratamiento de enfermedades respiratorias | |
| UY27740A1 (es) | Nuevos compuestos | |
| AR036586A1 (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen | |
| UY28752A1 (es) | Agentes terapeuticos | |
| UY28369A1 (es) | Agentes terapéuticos | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| AR061968A1 (es) | Ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-i-il-piridin-3-il-amino)-pirimidin-4-iloxi]-piperidin-i-carboxilico, composicion farmaceutica que lo comprende y un metodo de preparacion de la misma y el uso de este compuesto para el tratamiento de trastornos metabolicos | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR050261A2 (es) | Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| UY28376A1 (es) | Agentes terapéuticos | |
| PA8551001A1 (es) | Nuevos compuestos | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| JP6454335B2 (ja) | カテプシンシステインプロテアーゼ阻害剤 | |
| AR030007A1 (es) | Compuesto de ciclohexilo, su uso para la manufactura de un medicamento, agente de diagnostico, composicion farmaceutica que lo contiene, proceso para su preparacion, compuestos para su exclusivo uso en la preparacion de dichos compuestos de ciclohexilo, y metodo de tratamiento | |
| AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
| SE0403171D0 (sv) | New compounds | |
| UY28377A1 (es) | Agentes terapeuticos | |
| UY28896A1 (es) | Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros | |
| AR041678A1 (es) | Formas cristalinas de clorhidrato de donepezil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |